Search Results

You are looking at 131 - 140 of 295 items for :

  • "Neoadjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer

Sushmita Gordhandas, William A. Zammarrelli III, Eric V. Rios-Doria, Angela K. Green, and Vicky Makker

from ovarian cancer literature. Trends in the up-front treatment of advanced EC are changing, and neoadjuvant chemotherapy is now more commonly used than primary surgical cytoreduction for stage IVB endometrial cancer according to a recent analysis of

Full access

Principles of Management of Patients With Ampullary Adenocarcinoma

Presented by: Stephen W. Behrman

often in advanced disease and leads to significant downstaging,” said Dr. Behrman. “Utilization of radiotherapy as part of neoadjuvant chemotherapy regimens also seems to be a key component and warrants further investigation.” Genetics of Ampullary

Full access

Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Nilofer Azad, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, William Jeck, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Jennifer K. Maratt, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Eden Stotsky-Himelfarb, Anna Tavakkoli, Christopher G. Willett, Kristina Gregory, and Lisa Gurski

of neoadjuvant chemotherapy followed by chemoRT and surgery. 136 Of the 269 patients who were included, 91.1% completed chemotherapy, 88.1% completed chemoRT, and 89.2% underwent curative surgery. Five-year PFS and OS rates were 66.4% and 73

Full access

Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors

Stuart A. Grossman, Susannah Ellsworth, Jian Campian, Aaron T. Wild, Joseph M. Herman, Dan Laheru, Malcolm Brock, Ani Balmanoukian, and Xiaobu Ye

lymphopenia 2 months after beginning chemoradiation. 20 – 23 Notably, patients with stage III NSCLC who received neoadjuvant chemotherapy did not develop lymphopenia until they began treatment with radiation. 21 Relationships Between Severe TRL and

Full access

Ewing Sarcoma in a Patient With Cowden Syndrome

Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla, and Arun S. Singh

treated with 3 cycles of neoadjuvant chemotherapy consisting of vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide. She also received 45 Gy of neoadjuvant radiation therapy to her right pelvis. Subsequently, she

Full access

Comparison of Pathologic Stage in Patients Receiving Esophagectomy With and Without Preoperative Chemoradiation Therapy for Esophageal SCC

Bing-Yen Wang, Ping-Yi Lin, Shiao-Chi Wu, Hui-Shan Chen, Po-Kuei Hsu, Chih-Shiun Shih, Chao-Yu Liu, Chia-Chuan Liu, and Yao-Li Chen

Sjoquist KM Burmeister BH Smithers BM . Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysis . Lancet Oncol 2011 ; 12 : 681 – 692 . 7 Courrech Staal EF Aleman BM Boot H

Full access

NCCN Framework for Resource Stratification: A Framework for Providing and Improving Global Quality Oncology Care

Robert W. Carlson, Jillian L. Scavone, Wui-Jin Koh, Joan S. McClure, Benjamin E. Greer, Rashmi Kumar, Nicole R. McMillian, and Benjamin O. Anderson

excellence in the United States. (See Table 3 for legend.) proposed for situations in which RT, brachytherapy, and/or surgery are unavailable. Examples noted in blue text include neoadjuvant chemotherapy or neoadjuvant chemoradiation performed in

Full access

Neoadjuvant Radiotherapy Use in Locally Advanced Rectal Cancer at NCCN Member Institutions

Marsha Reyngold, Joyce Niland, Anna ter Veer, Dana Milne, Tanios Bekaii-Saab, Steven J. Cohen, Lily Lai, Deborah Schrag, John M. Skibber, William Small Jr, Martin Weiser, Neal Wilkinson, and Karyn A. Goodman

to 99% of patients receiving RT and only 53% of patients not receiving RT ( P <.0001). In the RT group, 21% received neoadjuvant chemotherapy only, 77% received both neoadjuvant and adjuvant, and 1% received adjuvant only. In contrast, among patients

Full access

The Role of Cytoreductive/Debulking Surgery in Ovarian Cancer

Mark T. Wakabayashi, Paul S. Lin, and Amy A. Hakim

Edited by Kerrin G. Robinson

action . J Clin Oncol 2007 ; 25 : 4168 – 4170 . 43. Onda T Matsumoto K Shibata T . Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology

Full access

Epithelial Ovarian Cancer

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner

, cholecystectomy, partial gastrectomy or cystectomy, ureteroneocystostomy, or distal pancreatectomy. 52 The therapeutic benefit of neoadjuvant chemotherapy followed by interval cytoreduction remains controversial (see next paragraph). 53 – 55 It may be